00:00It's Benzinga bringing Wall Street to Main Street.
00:02Novo Nordisk shares fell by 15% after its next-generation obesity drug failed to match
00:08Eli Lilly's, according to CNBC. Novo said Cagri-Sema failed to demonstrate non-inferiority
00:14in weight loss compared with Eli Lilly's terzepatide after an 84-week trial. Terzepatide
00:20is the active ingredient in Lilly's Munjaro and Zepbound, which have overtaken Novo's
00:24Ozempic and Weggevi in U.S. prescriptions. Novo's Copenhagen-listed shares dropped to 256
00:30Danish kroner, the lowest level since June 2021. Eli Lilly shares rose 3.5% in pre-market trading.
00:39Novo said it will explore additional trials, including higher-dose combinations. The update
00:44follows a nearly 50% stock decline in 2025 and guidance earlier this month that sales and
00:50profit growth could fall between 5% and 13% in 2026. CEO Mike Dowstar told CNBC that the company's
00:59performance is expected to decline before recovering. For all things money, visit Benzinga.com.
Comments